RxDoctor Payments Data

Rawa Sarji, DO

Cardiovascular Disease · Kalispell, MTNPI 1396978128

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 117 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 12.8% — the pattern of someone who eats at a lot of different presentations.

$2,273in general payments, 2019–2025

Across 117 payments — averaging $19.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$290
  • Novartis$286
  • Edwards Lifesciences$193
  • Abbott$166
  • AstraZeneca$147
  • Johnson & Johnson$145
  • plus $1K from 24 others

What the payments were for

  • Food & beverage$2,273100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,273 in reported general payments places this provider in the 60th percentile of 49 cardiovascular disease providers in Montana.

See all cardiovascular disease providers in Montana

Medicare billing

Part B allowed, 2024
$64,201
Medicare patients
521
Services billed
980

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban119$146,003
EntrestoSacubitril/Valsartan74$101,473
FarxigaDapagliflozin Propanediol69$69,247
JardianceEmpagliflozin75$59,493
Repatha SureclickEvolocumab34$23,820
Praluent PenAlirocumab11$11,854
Metoprolol Succinate223$3,635
Atorvastatin Calcium173$2,843
Rosuvastatin Calcium129$1,991
Isosorbide Mononitrate ErIsosorbide Mononitrate71$1,297
Losartan Potassium108$1,196
Torsemide53$1,135
Ezetimibe69$980
Amiodarone Hcl34$962
Chlorthalidone41$852

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$88$146,003119 claims
NovartisEntresto$286$101,47374 claims
AstraZenecaFarxiga$147$69,24769 claims
Boehringer IngelheimJardiance$290$59,49375 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 49 cardiovascular disease providers in Montana.

Other cardiovascular disease in Kalispell

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →